{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:20:56Z","timestamp":1787840456816,"version":"build-2784847793"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The advent of targeted biological agents has revolutionized the treatment approach for immune-mediated inflammatory diseases (IMIDs) in rheumatology and dermatology. However, these agents can lead to paradoxical immune-mediated inflammatory reactions (PRs), presenting challenges in clinical management. This case series aims to demonstrate diverse PRs associated with biologic therapies in IMID patients, shedding light on their clinical manifestations and management strategies. Five cases of IMID patients receiving targeted biologic therapies who developed PRs were retrospectively analyzed. Clinical presentations, histopathological findings, and treatment outcomes were documented. The PRs observed included pityriasis rosea-like drug reactions, eczematous reactions, lichenoid drug eruptions, and fixed drug eruptions. Histopathological examination revealed characteristic patterns corresponding to each PR type. Management strategies involved discontinuation or switching of biologic agents, resulting in resolution of cutaneous manifestations. This case series underscores the importance of recognizing and managing PRs in IMID patients undergoing biologic therapy. Further research is warranted to elucidate underlying mechanisms and guide therapeutic decisions, particularly with the emergence of biosimilars and potential cross-reactivity concerns.<\/jats:p>","DOI":"10.4103\/idoj.idoj_1115_24","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T13:25:32Z","timestamp":1761571532000},"page":"951-956","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["The Enigma of Paradoxical Reactions to Biological Therapies"],"prefix":"10.4103","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5003-0994","authenticated-orcid":false,"given":"Amira","family":"Elbendary","sequence":"first","affiliation":[{"name":"Dermatology Department, Kasr Alainy Faculty of Medicine, Cairo University, Al Giza, Giza Governorate, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9684-4731","authenticated-orcid":false,"given":"Hadeer","family":"Khedr","sequence":"additional","affiliation":[{"name":"Dermatology Department, Kasr Alainy Faculty of Medicine, Cairo University, Al Giza, Giza Governorate, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0467-9706","authenticated-orcid":false,"given":"Sara","family":"Elsayed","sequence":"additional","affiliation":[{"name":"Dermatology Department, Kasr Alainy Faculty of Medicine, Cairo University, Al Giza, Giza Governorate, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6190-8858","authenticated-orcid":false,"given":"Yomna A.","family":"Metwally","sequence":"additional","affiliation":[{"name":"Dermatology Department, Kasr Alainy Faculty of Medicine, Cairo University, Al Giza, Giza Governorate, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9701-844X","authenticated-orcid":false,"given":"Menna","family":"Rashwan","sequence":"additional","affiliation":[{"name":"Tropical Medicine, Hepatogastroenterology and Infectious Diseases, Kasr Alainy School of Medicine, Cairo University, Al Giza, Giza Governorate, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1816-871X","authenticated-orcid":false,"given":"Hany","family":"Shehab","sequence":"additional","affiliation":[{"name":"Tropical Medicine, Hepatogastroenterology and Infectious Diseases, Kasr Alainy School of Medicine, Cairo University, Al Giza, Giza Governorate, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9653-2938","authenticated-orcid":false,"given":"Mohammed","family":"El-Komy","sequence":"additional","affiliation":[{"name":"Dermatology Department, Kasr Alainy Faculty of Medicine, Cairo University, Al Giza, Giza Governorate, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"R1-20251030","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1002\/acr.22096","article-title":"Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists:Study using the Spanish registry of adverse events of biological therapies in rheumatic diseases","volume":"65","author":"Hern\u00e1ndez","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R2-20251030","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1586\/eci.09.18","article-title":"Paradoxical adverse effects of anti-TNF-alpha treatment:Onset or exacerbation of cutaneous disorders","volume":"5","author":"Viguier","year":"2009","journal-title":"Expert Rev Clin Immunol"},{"key":"R3-20251030","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3389\/fphar.2019.00282","article-title":"Paradoxical skin reactions to biologics in patients with rheumatologic disorders","volume":"10","author":"Garcovich","year":"2019","journal-title":"Front Pharmacol"},{"key":"R4-20251030","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/1346-8138.12562","article-title":"Pityriasis rosea and pityriasis rosea-like eruption:Can they be distinguished?","volume":"41","author":"Drago","year":"2014","journal-title":"J Dermatol"},{"key":"R5-20251030","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1080\/09546634.2020.1782816","article-title":"Secukinumab retreatment associated psoriasis flare with pustules","volume":"33","author":"El-Komy","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"R6-20251030","first-page":"939","article-title":"Infliximab-induced psoriasis in treatment of Crohn's disease-associated ankylosing spondylitis:Case report and review of 142 cases","volume":"12","author":"Famenini","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"R7-20251030","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jaci.2018.05.015","article-title":"Paradoxical psoriasis following anti-TNF therapy in ankylosing spondylitis:A population-based cohort study","volume":"142","author":"Bae","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"R8-20251030","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2340\/00015555-0839","article-title":"Cutaneous drug eruption with an interface dermatitis pattern due to anti-tumour necrosis factor-alpha agents:A relevant class-effect","volume":"90","author":"Garcovich","year":"2010","journal-title":"Acta Derm Venereol"},{"key":"R9-20251030","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/jdv.14673","article-title":"Immune response patterns in non-communicable inflammatory skin diseases","volume":"32","author":"Eyerich","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R10-20251030","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaad.2008.09.032","article-title":"Lichen planus-like eruptions:An emerging side effect of tumor necrosis factor-alpha antagonists","volume":"61","author":"Asarch","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"R11-20251030","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.immuni.2018.05.013","article-title":"Innate lymphoid cells:Diversity, plasticity, and unique functions in immunity","volume":"48","author":"Colonna","year":"2018","journal-title":"Immunity"},{"key":"R12-20251030","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1016\/j.jaip.2019.06.028","article-title":"Fixed drug eruption to biologics and role of lesional patch testing","volume":"7","author":"Li","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R13-20251030","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/ced.14400","article-title":"Fixed drug eruption secondary to adalimumab","volume":"46","author":"Bhadresha","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"R14-20251030","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/1346-8138.13762","article-title":"Cutaneous side-effects of biologics in immune-mediated disorders:A histopathological perspective","volume":"44","author":"Succaria","year":"2017","journal-title":"J Dermatol"},{"key":"R15-20251030","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.jaad.2020.11.071","article-title":"A systematic review of eczematous eruptions in patients receiving biologic therapy","volume":"85","author":"Mufti","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"R16-20251030","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/jdv.16246","article-title":"Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis:A systematic review","volume":"34","author":"Al-Janabi","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R17-20251030","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJMoa1104200","article-title":"Mutual antagonism of T cells causing psoriasis and atopic eczema","volume":"365","author":"Eyerich","year":"2011","journal-title":"N Engl J Med"},{"key":"R18-20251030","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/j.1468-3083.2007.02197.x","article-title":"Adalimumab-induced pityriasis rosea","volume":"21","author":"Rajpara","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R19-20251030","first-page":"383","article-title":"Pityriasis rosea during etanercept therapy","volume":"13","author":"Guarneri","year":"2009","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R20-20251030","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.clinthera.2017.03.014","article-title":"Comparing originator biologics and biosimilars:A review of the relevant issues","volume":"39","author":"Blandizzi","year":"2017","journal-title":"Clin Ther"},{"key":"R21-20251030","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1093\/rheumatology\/kead318","article-title":"The predictors of paradoxical reactions, especially psoriasis, to biologic therapy-findings from the TReasure database:A 5-year follow-up study","volume":"62","author":"Yagiz","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"R22-20251030","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/jdv.16980","article-title":"Immunogenicity of biologic therapies in psoriasis:Myths, facts and a suggested approach","volume":"35","author":"Tsakok","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Indian Dermatology Online Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.idoj_1115_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:23:11Z","timestamp":1787836991000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.idoj_1115_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/idoj.idoj_1115_24","relation":{},"ISSN":["2229-5178","2249-5673"],"issn-type":[{"value":"2229-5178","type":"print"},{"value":"2249-5673","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"2024-11-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}